Literature DB >> 28762197

Sequence, Structural Analysis and Metrics to Define the Unique Dynamic Features of the Flap Regions Among Aspartic Proteases.

Lara McGillewie1, Muthusamy Ramesh1, Mahmoud E Soliman2.   

Abstract

Aspartic proteases are a class of hydrolytic enzymes that have been implicated in a number of diseases such as HIV, malaria, cancer and Alzheimer's. The flap region of aspartic proteases is a characteristic unique structural feature of these enzymes; and found to have a profound impact on protein overall structure, function and dynamics. Flap dynamics also plays a crucial role in drug binding and drug resistance. Therefore, understanding the structure and dynamic behavior of this flap regions is crucial in the design of potent and selective inhibitors against aspartic proteases. Defining metrics that can describe the flap motion/dynamics has been a challenging topic in literature. This review is the first attempt to compile comprehensive information on sequence, structure, motion and metrics used to assess the dynamics of the flap region of different aspartic proteases in "one pot". We believe that this review would be of critical importance to the researchers from different scientific domains.

Entities:  

Keywords:  Aspartic proteases; Flap dynamics; Hydrolytic enzymes; Protein flexibility

Mesh:

Substances:

Year:  2017        PMID: 28762197     DOI: 10.1007/s10930-017-9735-9

Source DB:  PubMed          Journal:  Protein J        ISSN: 1572-3887            Impact factor:   2.371


  116 in total

1.  Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity.

Authors:  R Yan; M J Bienkowski; M E Shuck; H Miao; M C Tory; A M Pauley; J R Brashier; N C Stratman; W R Mathews; A E Buhl; D B Carter; A G Tomasselli; L A Parodi; R L Heinrikson; M E Gurney
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

2.  Purification and cloning of amyloid precursor protein beta-secretase from human brain.

Authors:  S Sinha; J P Anderson; R Barbour; G S Basi; R Caccavello; D Davis; M Doan; H F Dovey; N Frigon; J Hong; K Jacobson-Croak; N Jewett; P Keim; J Knops; I Lieberburg; M Power; H Tan; G Tatsuno; J Tung; D Schenk; P Seubert; S M Suomensaari; S Wang; D Walker; J Zhao; L McConlogue; V John
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

3.  Closing of the flaps of HIV-1 protease induced by substrate binding: a model of a flap closing mechanism in retroviral aspartic proteases.

Authors:  Gergely Tóth; Attila Borics
Journal:  Biochemistry       Date:  2006-05-30       Impact factor: 3.162

Review 4.  Physiology of local renin-angiotensin systems.

Authors:  Martin Paul; Ali Poyan Mehr; Reinhold Kreutz
Journal:  Physiol Rev       Date:  2006-07       Impact factor: 37.312

5.  Plasmodium falciparum ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems.

Authors:  Jun Liu; Eva S Istvan; Ilya Y Gluzman; Julia Gross; Daniel E Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-26       Impact factor: 11.205

6.  Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A.

Authors:  S Seelmeier; H Schmidt; V Turk; K von der Helm
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

7.  Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance.

Authors:  W R Scott; C A Schiffer
Journal:  Structure       Date:  2000-12-15       Impact factor: 5.006

Review 8.  Renin inhibition: what are the therapeutic opportunities?

Authors:  Naomi D L Fisher; Norman K Hollenberg
Journal:  J Am Soc Nephrol       Date:  2005-02-09       Impact factor: 10.121

9.  Crystal structures of native and inhibited forms of human cathepsin D: implications for lysosomal targeting and drug design.

Authors:  E T Baldwin; T N Bhat; S Gulnik; M V Hosur; R C Sowder; R E Cachau; J Collins; A M Silva; J W Erickson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

10.  Structural basis for plasmepsin V inhibition that blocks export of malaria proteins to human erythrocytes.

Authors:  Anthony N Hodder; Brad E Sleebs; Peter E Czabotar; Michelle Gazdik; Yibin Xu; Matthew T O'Neill; Sash Lopaticki; Thomas Nebl; Tony Triglia; Brian J Smith; Kym Lowes; Justin A Boddey; Alan F Cowman
Journal:  Nat Struct Mol Biol       Date:  2015-07-27       Impact factor: 15.369

View more
  5 in total

1.  Delving into the Characteristic Features of "Menace" Mycobacterium tuberculosis Homologs: A Structural Dynamics and Proteomics Perspectives.

Authors:  Adeniyi T Adewumi; Pritika Ramharack; Opeyemi S Soremekun; Mahmoud E S Soliman
Journal:  Protein J       Date:  2020-04       Impact factor: 2.371

2.  A flap motif in human serine hydroxymethyltransferase is important for structural stabilization, ligand binding, and control of product release.

Authors:  Sakunrat Ubonprasert; Juthamas Jaroensuk; Wichai Pornthanakasem; Nuntaporn Kamonsutthipaijit; Peerapong Wongpituk; Pitchayathida Mee-Udorn; Thanyada Rungrotmongkol; Onuma Ketchart; Penchit Chitnumsub; Ubolsree Leartsakulpanich; Pimchai Chaiyen; Somchart Maenpuen
Journal:  J Biol Chem       Date:  2019-05-22       Impact factor: 5.157

3.  Unveiling a New Era in Malaria Therapeutics: A Tailored Molecular Approach Towards the Design of Plasmepsin IX Inhibitors.

Authors:  Geraldene Munsamy; Mahmoud E S Soliman
Journal:  Protein J       Date:  2019-12       Impact factor: 2.371

Review 4.  A target safety assessment of the potential toxicological risks of targeting plasmepsin IX/X for the treatment of malaria.

Authors:  Jane Barber; Phumzile Sikakana; Claire Sadler; Delphine Baud; Jean-Pierre Valentin; Ruth Roberts
Journal:  Toxicol Res (Camb)       Date:  2021-02-15       Impact factor: 3.524

5.  Egress and invasion machinery of malaria: an in-depth look into the structural and functional features of the flap dynamics of plasmepsin IX and X.

Authors:  Geraldene Munsamy; Pritika Ramharack; Mahmoud E S Soliman
Journal:  RSC Adv       Date:  2018-06-13       Impact factor: 4.036

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.